Call 888-776-0942 from 8 a.m. to 10 p.m. Eastern Time

Piscataway, New Jersey, April 23, 2021/PRNewswire/ - MSN laboratory in Hyderabad, India received FDA approval to sell its generic albendazole 200 mg tablets (AB rating Albenza©), Droxidopa 100mg, 200mg, 300mg capsules (AB rated Northera ©), deferasirox granules 180mg, 360mg sachets (AB rated Jadenu Sprinkles©) and pregabalin ER 82.5 mg, 165 mg, 330 mg tablets, (AB rated Lyrica CR©) are under the Novadoz label. Novadoz is the US sales and marketing subsidiary of MSN's finished dosage form portfolio. The company has begun shipping all products approved in the first quarter of 2021.

Albendazole 200mg is sold in 2-piece bottles. It is suitable for the treatment of neurocysticercosis, an infection caused by pork tapeworms in the muscles, brain, and eyes that can cause seizures, brain swelling, and vision problems. The brand and generic drugs reported a total of US$26.9 million in sales in the last 12 months.

Doxydopa 100mg, 200mg and 300mg are available in 30 bottles. It is suitable for the symptomatic treatment of dizziness, dizziness or fainting/fainting caused by neurogenic orthostatic hypotension (a sudden drop in blood pressure). Novadoz participated in the first day of the product release, which coincided with the expiration of the brand exclusive period. The brand's reported sales in the previous 12 months totaled 366 million U.S. dollars. Novadoz also provides a patient e-voucher assistance program for eligible consumers who need assistance to cover the co-payment of out-of-pocket prescriptions they paid for Droxidopa. Visit NovadozPharma.com to learn more about the program.

The products they have recently received FDA approval include niche products, 180 mg and 360 mg deferasirox granules, 30 packets per box. This product is used to treat persistently high levels of iron in the body caused by multiple blood transfusions. It is also used to treat high iron levels in patients with certain blood diseases that do not require blood transfusions. Other niche products include pregabalin ER 82.5 mg, 165 mg and 330 mg tablets, 30 bottles per bottle. This product is suitable for the treatment of pain caused by nerve damage caused by diabetes or shingles (shingles).

Seshu Akula, President of Novadoz North America Generic Drugs, said: “The first quarter of 2021 is a very active period for the MSN/Novadoz organization and has obtained four FDA approvals. We have successfully brought these products to the market while keeping up with our existing The product line was created by the pandemic."

He added: “MSN’s position as a global leader in the API field provides Novadoz with a scale and leverage comparable to some of the largest generic drug companies in the United States. The injection pipeline and the specialty products we expect to launch in the next 10 years."

MSN Labs is engaged in the development and manufacturing of API (active pharmaceutical ingredient), KSM (key starting material) and product intermediates. MSN is the global leader in this category. In addition, the company produces oral solid, liquid, and specialty injection products in 65 markets around the world, and operates as Novadoz Pharmaceuticals in the United States.

For more information, please visit the company's website NovadozPharma.com and MSNLabs.com.

Contact: Tom DeStefano Novadoz Pharmaceuticals Vice President of Sales and Marketing (848) 200-1909

Cision Distribution 888-776-0942 8 a.m. to 9 p.m. Eastern Time